ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.

• Váldodahkkit: Rocio Rivero (Dahkki), Mónica Inés Esteva (Dahkki), Erya Huang (Dahkki), Leylen Colmegna (Dahkki), Jaime Altcheh (Dahkki), Ulrike Grossmann (Dahkki), Andrés Mariano Ruiz (Dahkki), CHICO and CHICO SECURE Study Groups (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Public Library of Science (PLoS), 2023-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

<h4>Background</h4>Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administer...